Edition:
India

Bellerophon Therapeutics Inc (BLPH.OQ)

BLPH.OQ on NASDAQ Stock Exchange Global Market

0.65USD
1:01am IST
Change (% chg)

$0.00 (+0.15%)
Prev Close
$0.65
Open
$0.65
Day's High
$0.67
Day's Low
$0.65
Volume
8,644
Avg. Vol
77,739
52-wk High
$3.30
52-wk Low
$0.47

Latest Key Developments (Source: Significant Developments)

Bellerophon Therapeutics Reports Q4 Loss Per Share Of $0.02
Thursday, 14 Mar 2019 

March 14 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FOURTH QUARTER AND FULL-YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.02.AS OF DECEMBER 31, 2018, HAD CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES OF $16.6 MILLION.  Full Article

Bellerophon Therapeutics - Public Offering Of 10 Million Common Shares Priced At $0.70 Per Share
Wednesday, 23 Jan 2019 

Jan 23 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON ANNOUNCES PRICING OF $7 MILLION PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 10.0 MILLION COMMON SHARES PRICED AT $0.70PER SHARE.  Full Article

Bellerophon Therapeutics Inc Announces Proposed Public Offering Of Common Stock
Wednesday, 23 Jan 2019 

Jan 22 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK.BELLEROPHON THERAPEUTICS INC - BELLEROPHON INTENDS TO USE NET PROCEEDS FROM THIS OFFERING TO FUND WORKING CAPITAL.  Full Article

Bellerophon Therapeutics Q1 Shr Loss $0.04
Thursday, 10 May 2018 

May 10 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON PROVIDES BUSINESS UPDATE AND REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS.BELLEROPHON THERAPEUTICS Q1 BASIC EARNINGS PER SHARE $0.07 .BELLEROPHON THERAPEUTICS INC - QTRLY LOSS PER SHARE $0.04.  Full Article

Bellerophon Reaches Agreement With FDA On Study Design Of Phase 2b Trial Of INOpulse
Tuesday, 8 May 2018 

May 8 (Reuters) - Bellerophon Therapeutics Inc ::BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON REACHES AGREEMENT WITH FDA ON STUDY DESIGN OF PHASE 2B TRIAL OF INOPULSE® FOR TREATMENT OF PULMONARY HYPERTENSION ASSOCIATED WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE.BELLEROPHON THERAPEUTICS - PHASE 2B STUDY TO BE A DOUBLE-BLIND, PLACEBO-CONTROLLED, CLINICAL TRIAL IN ABOUT 90 PH-COPD PATIENTS.BELLEROPHON THERAPEUTICS - PRIMARY END POINT OF STUDY WILL BE SIX-MINUTE WALKING DISTANCE, STUDY TO ALSO ASSESS MULTIPLE SECONDARY ENDPOINTS.  Full Article

Bellerophon Therapeutics reports Q3 loss per share $0.22
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon provides business update and reports third quarter 2017 financial results.Q3 loss per share $0.22.Says ‍ phase 2a study for inopulse met its primary endpoint​.  Full Article

Bellerophon Therapeutics says selling stockholders may offer, resell up to 38.9 mln shares - SEC filing
Wednesday, 25 Oct 2017 

Oct 24 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon Therapeutics Inc files to say selling stockholders may offer and resell up to 38.9 million shares of co's common stock - SEC filing.Bellerophon Therapeutics Inc - the selling stockholders will receive all of the proceeds from any sales of the shares offered.  Full Article

Bellerophon announces $23 million private placement
Wednesday, 27 Sep 2017 

Sept 27 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces $23 million private placement.Bellerophon Therapeutics Inc - ‍financing was led by Puissance Capital Management and Venrock Healthcare Capital Partners​.Bellerophon Therapeutics Inc - will sell about 19.4 million shares of stock, warrants to purchase about 19.4 million shares of stock for about $23.4 million.  Full Article

Bellerophon announces positive top line Phase 2 data of INOpulse
Tuesday, 5 Sep 2017 

Sept 5 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon announces positive top line Phase 2 data of INOpulse for treatment of Pulmonary Hypertension associated with Chronic Obstructive Pulmonary Disease.Bellerophon Therapeutics Inc - ‍acute results showed a statistically significant increase in blood vessel volume on INO compared to baseline​.Bellerophon Therapeutics Inc - ‍study therapy was well tolerated with no related safety concerns​.Bellerophon Therapeutics Inc - ‍is currently conducting a Phase 3 trial for INOpulse for treatment of Pulmonary Arterial Hypertension​.Bellerophon Therapeutics Inc - ‍top-line data for Phase 3 trial of INOpulse expected in 2018​.  Full Article

Bellerophon reports Q2 loss per share $0.12
Monday, 7 Aug 2017 

Aug 7 (Reuters) - Bellerophon Therapeutics Inc :Bellerophon reports second quarter 2017 financial results and provides business update.Q2 loss per share $0.12.Bellerophon Therapeutics - Anticipate reporting top line results for inovation-1 phase 3 trial in PAH in 2018.  Full Article